Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kwan Soo Byun, Seung Woon Paik, Young Suk Lim, Han Chu Lee, Kwang Hyub Han, Kwan Sik Lee
Korean J Intern Med. 2009;24(3):203-211. Published online 2009 Aug 26 DOI: https://doi.org/10.3904/kjim.2009.24.3.203
Citations to this article as recorded by 
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
Pharmacology Research & Perspectives.2021;[Epub] CrossRef
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
Gut and Liver.2020; 14(6): 775. CrossRef
KASL clinical practice guidelines: management of hepatitis C
Clinical and Molecular Hepatology.2016; 22(1): 76. CrossRef
Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
Chansoo Moon, Kyu Sik Jung, Do Young Kim, Oidov Baatarkhuu, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Sang Hoon Ahn, Kwang-Hyub Han
Digestive Diseases and Sciences.2015; 60(2): 573. CrossRef
Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment
Jung Hyun Kwon
The Korean Journal of Gastroenterology.2015; 66(2): 131. CrossRef
KASL clinical practice guidelines: Management of Hepatitis C
Clinical and Molecular Hepatology.2014; 20(2): 89. CrossRef
The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial
Jung Hyun Kwon, Si Hyun Bae, Youn Jae Lee, Jin-Woo Lee, Young Seok Kim, Jae Seok Hwang, Won Young Tak, Jeong Won Jang, Byung Seok Lee, June Sung Lee, Chun Kyon Lee, Soon Koo Baik, Neung Hwa Park, Tae Hee Lee, Dong Joon Kim, Jae-Seok Choi, Jae-Gook Shin, H
Hepatology International.2013; 7(4): 1000. CrossRef
Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis
Yueqiu Luo, Caixia Jin, Zongxin Ling, Xiaozhou Mou, Qiong Zhang, Charlie Xiang
Gene.2013; 513(2): 292. CrossRef
Polymorphisms nearInterleukin 28BGene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence
Dong Hyeon Lee, Yuri Cho, Ji Yeon Seo, Jung Hee Kwon, Eun Ju Cho, Eun Sun Jang, Min-Sun Kwak, Jae Youn Cheong, Sung Won Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hyo-Suk Lee, Chung Yong Kim, Hyoung Doo Shin, Yoon Jun Kim
Intervirology.2013; 56(2): 84. CrossRef
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin
KwangSoo Lyoo, Myeong Jun Song, Wonhee Hur, Jung Eun Choi, Sung Woo Hong, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Sang Wook Choi, Eui-Cheol Shin, Seung Kew Yoon
Journal of Clinical Virology.2011; 52(4): 363. CrossRef